Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lacosamide for SCN9A-associated small fiber neuropathy pain
NL-OMON41621Phase 3Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lacosamide in small fiber neuropathy (SFN) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Change from baseline in average pain score. Started Nov 2014; status: active, not recruiting.
02
Drugs
lacosamide
03
Conditions
small fiber neuropathy (SFN)
Beyond the preview
Go deeper on NL-OMON41621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41621.